The evolution of research and development in the pharmaceutical industry: toward the open innovation model – can pharma reinvent itself?

Ram Subramanian, Jeffrey H. Toney and C. Jayachandran

International Journal of Business Innovation and Research, 2011, vol. 5, issue 1, 63-74

Abstract: The global pharmaceutical industry is facing diminishing returns from its massive investment in research and development. This is particularly troublesome because the industry has long enjoyed monopoly rents that come from innovative new drugs. The purpose of this paper is to examine the extant R&D practices in the industry and make a strong case for a shift to the open innovation model. Potential roadblocks to adopting the open innovation model are identified as well as ways to overcome these roadblocks. This conceptual paper makes use of archival R&D and sales data to support its contentions.

Keywords: open innovation; pharmaceutical industry; pharma; diminishing returns; monopoly rents; innovative drugs; new drugs; medicines; roadblocks; sales data; globalisation; business innovation; R&D investment; research and development. (search for similar items in EconPapers)
Date: 2011
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
http://www.inderscience.com/link.php?id=37257 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ids:ijbire:v:5:y:2011:i:1:p:63-74

Access Statistics for this article

More articles in International Journal of Business Innovation and Research from Inderscience Enterprises Ltd
Bibliographic data for series maintained by Sarah Parker ().